Publications

Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Cologuard (Exact Sciences Corp.)

Focus of the Report: This report examines the analytical validity, clinical validity, and clinical utility of the Cologuard stool DNA test for the qualitative detection of colorectal neoplasia–associated DNA markers and for the presence of occult hemoglobin in human stool, which may indicate the presence of colorectal cancer (CRC) or advanced a…

read more

Anifrolumab for Systemic Lupus Erythematosus

Anifrolumab is an investigational fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of all type I IFNs. It is proposed for the treatment of adults with moderately to severely active systemic lupus erythematosus (SLE) who are receiving standard care.

read more

Intravenous Ketamine for Chronic Nonmalignant Pain

Focus of the Report: This report focuses on the use of intravenous (IV) ketamine for the treatment of chronic nonmalignant pain.

Technology Description: The hydrochloride (HCl) acid salt of ketamine is a rapid-acting phencyclidine anesthetic indicated for the induction of anesthesia prior to the administration of other general anesthetic agents, as a s…

read more

Retifanlimab for Squamous Cell Anal Cancer

Retifanlimab is an investigational intravenous humanized monoclonal antibody that inhibits the activity of programmed death-1 (PD-1). By blocking PD-1, retifanlimab acts as an immune checkpoint inhibitor, freeing T cells to kill cancer cells and boosting immune system response against certain cancers. Retifanlimab is proposed as a monotherapy for locally advanced and metastat…

read more